β-D-N4-hydroxycytidine, a metabolite of molnupiravir, exhibits in vitro antiviral activity against rabies virus

Konishi, Kei; Kusakabe, Shinji; Kawaguchi, Nijiho; Shishido, Takao; Ito, Naoto; Harada, Michiko; Inoue, Satoshi; Maeda, Ken; Hall, William W.; Orba, Yasuko; Sawa, Hirofumi; Sasaki, Michihito; Sato, Akihiko

β-D-N4-hydroxycytidine, a metabolite of molnupiravir, exhibits in vitro antiviral activity against rabies virus

Konishi, Kei; Kusakabe, Shinji; Kawaguchi, Nijiho et al.

Antiviral research, 2024, 229, 105977

Permalink : https://hdl.handle.net/2115/96169

このアイテムのアクセス数:97件（2026-08-10 20:56 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
RABV_NHC_Maintext_revise final_Clean	pdf	2.85 MB	42
RABV_NHC_Suppl figure_revised final	pdf	226 KB	55	Supplementary data

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/96169
タイトル	β-D-N4-hydroxycytidine, a metabolite of molnupiravir, exhibits in vitro antiviral activity against rabies virus
著者	Konishi, Kei ; Kusakabe, Shinji ; Kawaguchi, Nijiho ; Shishido, Takao ; Ito, Naoto ; Harada, Michiko ; Inoue, Satoshi ; Maeda, Ken ; Hall, William W. ; Orba, Yasuko ; Sawa, Hirofumi ; Sasaki, Michihito ; Sato, Akihiko
著者名 Konishi, Kei
著者名 Kusakabe, Shinji
著者名 Kawaguchi, Nijiho
著者名 Shishido, Takao
著者名 Ito, Naoto
著者名 Harada, Michiko
著者名 Inoue, Satoshi
著者名 Maeda, Ken
著者名 Hall, William W.
e-Rad_Researcher 60507169 著者名 Orba, Yasuko
e-Rad_Researcher 30292006 著者名 Sawa, Hirofumi
e-Rad_Researcher 70609403 著者名 Sasaki, Michihito
著者名 Sato, Akihiko
言語	英語
キーワード	Rabies virus
	Antiviral
	beta-D-N4-hydroxycytidine
	Molnupiravir
	Nucleoside analog
発行日	2024-09
出版者	Elsevier
収録物名	Antiviral research
巻(号)	229
ページ	105977
抄録	Rabies is a fatal neurological disorder caused by rabies virus (RABV) infection. Approximately 60,000 patients die from rabies annually, and there are no effective treatments for this disease. Nucleoside analogs are employed as antiviral drugs based on their broad antiviral spectrum, and certain nucleoside analogs have been reported to exhibit anti-RABV activity. The nucleoside analog beta-D-N4-hydroxycytidine (NHC) has antiviral effects against a range of RNA viruses. Molnupiravir (MPV), a prodrug of NHC, is clinically used as an oral antiviral drug for coronavirus infections. Despite its broad-spectrum activity, the antiviral activity of NHC against RABV remains unclear. In this study, we reveal that NHC exhibits comparable in vitro anti-RABV activity as ribavirin and favipiravir (also known as T-705) with a 90% effective concentration of 6 mu M in mouse neuroblastoma cells. NHC reduced viral loads in neuronal and nonneuronal cells in a dose-dependent manner. Both laboratory and field RABVs (fixed and street strains, respectively) were susceptible to NHC. However, no increase in survival or reduction in viral titers in the brain was observed in RABV-infected mice treated prophylactically with MPV. These findings highlight the potential and challenges of NHC in the treatment of RABV infection.
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
権利情報	Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
権利情報	© 2024. This manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/
PISSN	0166-3542
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1016/j.antiviral.2024.105977